• CEO Kwak Noh-Jung and key executives, alongside global VCs and startup leaders, attend the inaugural ‘SK hynix Ventures Day’ in Silicon Valley
• Company to expand investments across the entire AI ecosystem
• Discussing strategies to strengthen partnerships with global venture firms and investors in future technology fields such as AI data centers and optical-based systems

SEOUL, South Korea, Sept. 18, 2026 — SK hynix Inc. (or “the company”, www.skhynix.com) announced today the launch of its corporate venture capital (CVC) brand, “SK hynix Ventures,” aimed at expanding strategic partnerships within the global AI ecosystem and securing future innovative technologies.

To mark the occasion, SK hynix held the inaugural “SK hynix Ventures Day” in Silicon Valley, where executives shared investment strategies with global venture capitalists and startup representatives while discussing future technological cooperation to respond to shifts in the AI industry.

The event was attended by CEO Kwak Noh-Jung and key executive leadership, alongside representatives from global VC firms and executives from leading startups.

• Expanding Beyond Tech Sensing to Become a Strategic Partner in the AI Ecosystem

Since 2015, SK hynix has operated a CVC organization, pursuing both direct investments and indirect investments via fund commitments in promising early-stage startups within the semiconductor and emerging tech sectors. By investing in enterprises across key regions including the U.S., China, Israel, and Japan, the company has achieved returns exceeding twice its cumulative investment to date. Furthermore, it has accumulated a track record of discovering new supply chains and customers by pursuing technological collaborations—such as joint equipment development and Proof of Concept (PoC)—with portfolio companies.

While past CVC activities focused primarily on “Tech Sensing” to explore future technology trends and “Path Finding” to discover new business opportunities, the company now plans to expand its CVC scope. Driven by recent advancements in AI technology and industry expansion, the role will evolve from simply discovering promising companies to leading collaborative innovation across the entire ecosystem.

• Discussing Cooperation in AI Computing, Data Centers, and Optical Interconnect

Through SK hynix Ventures, the company plans to broaden its investment scope from traditional semiconductors and emerging tech to the broader AI ecosystem. SK hynix aims to discover technologies and companies with high growth potential in core AI industry sectors—including AI computing, data centers, system software, and optical interconnect—and continually expand its CVC investments.

Meanwhile, the event was attended by promising startups in the U.S. AI computing and data center technology sectors. These companies shared perspectives on future technological innovations, discussing the growing importance of computing, memory, and system software innovations driven by advanced AI models, alongside the performance and power efficiency of optical-based systems for AI data centers.

“Competitiveness in the AI era stems not just from rapidly securing innovative technologies, but from ecosystem capabilities where customers, partners, and startups create new value together,” said Kwak Noh-Jung, CEO of SK hynix. “Through SK hynix Ventures, we will support the growth of promising companies and grow into a global partner that jointly designs the future of AI infrastructure based on strategic investments and technological cooperation.”

About SK hynix Inc.
SK hynix Inc., headquartered in Korea, is the world’s top-tier semiconductor supplier offering Dynamic Random Access Memory chips (“DRAM”) and flash memory chips (“NAND flash”) for a wide range of distinguished customers globally. The Company’s common shares are traded on the Korea Exchange, its American Depositary Shares are traded on NASDAQ, and its Global Depository Shares are listed on the Luxembourg Stock Exchange. Further information about SK hynix is available at www.skhynix.com, news.skhynix.com.

SOURCE SK hynix Inc.

HCTI to serve as U.S. technology and capital-markets partner, bringing AI, cloud and data expertise as ARCB and Kanzun launch cross-border healthcare investment platform

PLEASANTON, Calif., Sept. 17, 2026 — Healthcare Triangle, Inc. (Nasdaq: HCTI) (“HCTI” or the “Company”), a U.S.-based healthcare technology company, today announced that it has signed on as the U.S. technology and capital-markets partner for a new fund built to move Malaysian healthcare companies to the world stage. The Kanzun-ARCB Growth Fund launched through a Memorandum of Understanding signed in Kuala Lumpur, Malaysia, pairing Dubai-based ARCB Investment LLC’s (“ARCB”) capital network with Kanzun Ventures Management Sdn. Bhd.’s (“Kanzun”) deal experience on the ground in Malaysia. HCTI’s role will be to get qualifying companies ready, technologically and financially, for a successful run at the U.S. capital markets.

ARCB brings roughly AED 300 million in assets under management and a network of family offices, institutional investors and strategic partners across the Middle East and Asia. The firm opened its Asia-Pacific office in Kuala Lumpur in April 2026, and the Kanzun-ARCB Growth Fund marks its first major platform launch in the region. Together with Kanzun and HCTI, the three parties are building a structured corridor connecting Malaysian healthcare companies to Middle Eastern capital and, from there, to U.S. capital markets.

How the Partnership Will Work

Kanzun will lead the deal sourcing, due diligence, valuation and portfolio development in Malaysia, identifying healthcare companies with real growth potential. ARCB anchors the fund’s capital formation, drawing on its investor network across the Middle East and Asia. HCTI steps in once a target companies are ready for thier next stage of growth. The Company applies its Nasdaq-listed experience and its expertise in artificial intelligence, cloud, data and digital infrastructure to help build the technology foundation and market readiness a U.S. expansion requires.

Management’s Comments

Dr Suresh Venkatachari, Founder and Head of M&A of Healthcare Triangle, Inc., said: “We are pleased to collaborate with ARCB and Kanzun Ventures in evaluating opportunities within the Malaysian AI and healthcare sector. We look forward to supporting qualifying companies in their AI technology transformation and evaluating appropriate strategic pathways to expand in U.S. markets.”

Dr Chaskar U., Chief Executive Officer of ARCB Group, said: “Since establishing our ASEAN presence in Kuala Lumpur this April, we have been deliberate about where and how ARCB deploys capital in this region. Malaysia’s healthcare sector is full of founders who have built genuinely strong businesses but have not yet had access to the institutional capital, governance and international positioning needed to compete globally. That is precisely the gap ARCB exists to close. With Kanzun’s execution capability on the ground and Healthcare Triangle’s technology and U.S. market experience, we are building more than a fund — we are building a corridor that connects Malaysian healthcare champions to Middle Eastern capital and, from there, to the U.S. capital markets. This is what our ASEAN strategy was always designed to deliver.”

Mr Loganathan S., Chief Executive Officer of Kanzun Ventures Management Sdn. Bhd., said: “Malaysia has healthcare entrepreneurs who have spent many years building strong businesses, but many of these companies remain relatively small from an international capital-market perspective. Working with ARCB gives us access to an international capital network, while our collaboration with Healthcare Triangle provides an important connection to healthcare technology and the U.S. market.”

About Healthcare Triangle, Inc.

Healthcare Triangle, Inc. (Nasdaq: HCTI), based in Pleasanton, California, reinforces healthcare progress through breakthrough technology and extensive industry knowledge and expertise. The Company supports healthcare organizations — including hospitals and health systems, payers, and pharma/life sciences organizations — in their effort to improve health outcomes through better utilization of the data and information technologies they rely on. Healthcare Triangle’s Cloud and Data Platform (CaDP), marketed as CloudEz™ and DataEz™, has achieved HITRUST Risk-based, 2-year (r2) Certified status, demonstrating to clients the highest standards for data protection and information security. Healthcare Triangle enables the adoption of new technologies, data enlightenment, business agility, and response to immediate business needs and competitive threats. The highly regulated healthcare and life sciences industries rely on Healthcare Triangle for expertise in digital transformation encompassing cloud, security and compliance, data lifecycle management, healthcare interoperability, and clinical and business performance optimization.

About ARCB Investment LLC

ARCB Investment LLC is a UAE fund house established in 2022 and a Mainland investment management licensed company (License No. 1041252), under the leadership of Chairman His Excellency Dr Mohammed Saeed Al Kindi, a former UAE Minister and diplomat, and Chief Executive Officer Dr Chaskar U. ARCB manages assets under management of approximately AED 300 million across ten sectors, including energy, water, healthcare, education, agriculture, industry, tourism, sports, technology and commercial real estate. ARCB is a participant of the United Nations Global Compact.

About Kanzun Ventures Management Sdn. Bhd.

Kanzun Ventures Management Sdn. Bhd. is a Malaysia-based venture capital management corporation registered with the Securities Commission Malaysia. Kanzun focuses on identifying, structuring and developing investment opportunities with the potential for significant growth and strategic value, including opportunities across healthcare and healthcare-related industries.

Forward-Looking Statements and Safe Harbor Notice

This press release contains forward-looking statements concerning the proposed collaboration among Healthcare Triangle, Inc., ARCB Investment LLC and Kanzun Ventures Management Sdn. Bhd., including statements regarding potential investments, acquisitions, capital raising, technology integration, strategic transactions and potential U.S. capital-market opportunities for Malaysian healthcare companies. References to targeted healthcare companies or segments in this announcement should not be interpreted as confirmation that any acquisition, investment, consolidation or U.S. listing has been completed. Any proposed transaction remains subject to due diligence, audit, valuation, negotiations, corporate and regulatory approvals, financing and the execution of definitive agreements. Nothing contained in this announcement constitutes an offer to sell or a solicitation of an offer to purchase securities or interests in any fund, company or investment vehicle. Any reference to Nasdaq or the U.S. capital markets represents a strategic objective or potential pathway only and does not constitute a representation or guarantee that any company will be listed on Nasdaq or complete any U.S. capital-market transaction.

All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate.” The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions, including market and other conditions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors outlined in the Company’s annual report on Form 10-K for the year ended December 31, 2025, on file with the Securities and Exchange Commission (the “SEC”) and in previous filings, subsequent filings and future periodic reports filed with the SEC. All the Company’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

Investor Contact

Healthcare Triangle, Inc.
1-800-617-9550
[email protected]

SOURCE Healthcare Triangle, Inc.

Silicon Valley lender is building a private-bank-style mortgage platform for founders, self-employed entrepreneurs, business owners and high-net-worth borrowers who don’t fit traditional agency underwriting

DANVILLE, Calif., Sept. 17, 2026 — As Non-QM mortgage lending continues to expand, RateSecure sees the market separating into two distinct segments: traditional alternative-credit lending and a private-bank-style approach designed for financially strong borrowers with complex income and wealth profiles.

“There are really two Non-QM markets emerging — traditional alternative-credit lending and private-bank-style lending for wealthy borrowers,” said Gurp Bhandal, Founder and CPO of RateSecure. “We built RateSecure around the second.”

For RateSecure, this is often a documentation gap, not a credit gap.

“Traditional mortgage underwriting works well for borrowers with predictable W-2 income, but entrepreneurship creates a different financial profile,” said Sam Bhandal, President and CEO of RateSecure. “A successful business owner shouldn’t become a difficult mortgage borrower simply because their income doesn’t fit neatly into a conventional calculation.”

For many self-employed borrowers, legitimate business deductions, reinvestment and multiple income sources can complicate qualification without necessarily indicating weaker financial strength.

Private-Bank Thinking at Silicon Valley Speed

Understanding a complex borrower is only part of the equation. In Silicon Valley’s ultra-competitive housing market, execution matters just as much as loan structure.

RateSecure is built to close complex loans in less than 10 days, giving founders, entrepreneurs and business owners the ability to compete on speed alongside borrowers with traditional W-2 income.

Complex wealth shouldn’t put a buyer at a competitive disadvantage.

“When a family finds the right home, the complexity of how they’ve built their wealth shouldn’t be the reason they lose it,” Gurp Bhandal said. “Our job is to understand the borrower, structure the financing correctly and execute at the speed the market demands.”

A Different Evolution of Non-QM

RateSecure believes the growth of self-employment, entrepreneurship and complex personal wealth is changing the role Non-QM plays in the mortgage industry.

Historically, Non-QM has often been viewed as an alternative for borrowers unable to qualify for conventional financing. RateSecure believes that definition increasingly misses an important part of the market.

“Non-QM isn’t simply about borrowers who can’t qualify conventionally,” Gurp Bhandal said. “There’s a growing segment of financially strong borrowers who simply need a more sophisticated way to document income and wealth.”

For RateSecure, those borrowers aren’t exceptions to its lending model. They are the reason the model exists.

“We’re building a mortgage company around founders, entrepreneurs, business owners and high-net-worth borrowers,” Sam Bhandal said. “The goal is to bring the level of understanding and individualized structuring associated with private banking into a modern mortgage platform.”

About RateSecure Financial

RateSecure Financial, Inc. is a California mortgage lender focused on founders, self-employed entrepreneurs, business owners, real estate investors and high-net-worth borrowers with complex income and wealth.

Complex Wealth. Strategic Lending. Exceptional Execution.

RateSecure Financial, Inc.
NMLS #2815879
CA DFPI California Financing Law License #60DBO-217750
675 Hartz Avenue, Suite 103
Danville, CA 94526
(866) 351-RATE
[email protected]

SOURCE RateSecure

LAFAYETTE, Ind. , Sept. 17, 2026 — Valley Oaks Health announced today that it has been awarded $828,375 through the Growing Rural Opportunities for Well-being (GROW) Region 3 Grant initiative to strengthen access to integrated healthcare services across rural communities in northwest central Indiana.

The funding is part of the Indiana Rural Health Transformation Program (Indiana RHTP), a statewide initiative designed to improve healthcare access, strengthen healthcare infrastructure, promote innovation, and support strategic partnerships that improve the health and well-being of Hoosiers.

Valley Oaks Health serves individuals and families across ten Indiana counties through a comprehensive system of behavioral health, primary care, addiction treatment, crisis intervention, care coordination, and community-based support services. The GROW award will help advance efforts to improve access to care, strengthen regional partnerships, and enhance services in rural communities where healthcare workforce shortages and transportation barriers often limit access to timely treatment.

At the community level, this funding will primarily support expansion of Primary Care access points in Attica, IN and Monticello, IN in the first half of CY2027 with further expansion planned next year.

“This investment reflects a shared commitment to improving the health and well-being of rural Hoosiers,” said Dan Arens, Chief Executive Officer of Valley Oaks Health. “Through collaboration with community partners and local stakeholders, we will continue expanding access to integrated healthcare services that address both physical and behavioral health needs close to home; encouraging local healthcare relationships.”

Approximately one in five Hoosiers lives in a rural community, and the Indiana Rural Health Transformation Program supports community-driven solutions that address local healthcare priorities. The five-year initiative emphasizes innovation, workforce development, infrastructure improvements, and regional collaboration to improve health outcomes across Indiana.

Valley Oaks Health remains committed to its mission of improving the health and happiness of our community, one person at a time, by delivering accessible, high-quality care regardless of an individual’s ability to pay.

About Valley Oaks Health

Valley Oaks Health is a nonprofit healthcare organization serving communities across northwest central Indiana. The organization provides integrated behavioral health, primary care, addiction treatment, crisis services, and community support programs designed to improve the health and well-being of individuals and families throughout the region.

www.valleyoaks.org

This Rural Health Transformation Program is supported by the Centers for Medicare & Medicaid Services (CMS) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $206,927,896.80 with 100 percent funded by CMS/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CMS/HHS, or the U.S. Government.

SOURCE Valley Oaks Health

LONDON, Sept. 17, 2026 /PRNewswire/ — Magentic, which provides AI digital workers for operations at large industrial companies, today announced an $18 million Series A. The round was raised a year after launch and led by Felicis, alongside existing investors Sequoia Capital and The Westly Group. Founded by McKinsey and OpenAI alumni, Magentic is leading the deployment of AI agents for the world’s largest manufacturers.

“The physical world is dealing with the biggest capex cycle in history, driven by AI demand, during a time of trade disruption and geopolitical challenges,” said Robin Van Aeken, CEO and co-founder of Magentic. “The companies that build the best intelligence into every decision they make will be the ones that compound their competitive advantage.”

The funding arrives as industrial and procurement teams face converging pressures from manufacturing demand, tariffs, and limited budget. Goldman Sachs projects roughly $8 trillion in AI capital spending between 2026 and 2031, much of it flowing into physical infrastructure that has to be sourced and built. Procurement workloads have grown roughly 10% year over year against just 1% budget growth.

AI digital workers for operations

Magentic’s AI digital workers are multi-agent systems that operate like virtual employees, working continuously inside the world’s largest manufacturers. This AI workforce works the way people do: on Microsoft Teams, on email, and inside a company’s own systems. They can take over work and own it end to end: deciding whether to buy or build, choosing the right supplier, negotiating contracts, running orders, and clearing invoices. Built for a scale only the world’s largest manufacturers face in billions of rows of data, tens of billions in spend, and decades-old fragmented systems still held together by Excel and aging ERPs, a single digital worker grows into a workforce spanning operations, with people always in command.

Magentic supports both indirect and direct spend. This includes the raw materials that go into products, where the most complex and valuable challenges lie. One customer now runs more than a million orders a year through Magentic AI agents; at another, they’ve already found $4 million in savings. Across a base of the Global 500, including three of the world’s ten largest beverage companies, Magentic typically delivers 2–5% savings, a 60% lift in data quality, and reduces tens of thousands of hours of manual work. This frees people to focus on partnering with suppliers, new product innovation, and strategy. Magentic sees human procurement teams growing bigger as their value per person goes up in the future.

“Supply chains are the least glamorous part of the economy, yet the most consequential, deciding what gets built and what does not. That’s also what makes them so hard to automate,” said Feyza Haskaraman, Partner at Felicis. “Getting an agent to understand a manufacturer’s complex systems well enough to take action inside them is no small feat, which is why we haven’t seen anyone else build autonomous AI workers for the physical economy.”

Scaling a secure AI workforce

With enterprise wary of AI agents acting inside critical systems, Magentic is built for demanding security bars. Controls include zero-data-retention agreements with major AI providers, deployment in any cloud environment, and secure, isolated deployments available in any data region.

The new funding will accelerate Magentic’s roadmap for AI agents, extend coverage across procurement and supply chain workflows, and deepen the long-horizon AI research that lets agents tackle the most complex optimization problems in procurement and supply chains.

“Bringing frontier AI to the physical world requires pushing beyond AI systems with limited context windows. We’re building AI that can diagnose problems, plan the fixes, take action, and see the work through across terabytes of multimodal data at once,” said Odhran O’Donoghue, CTO and co-founder of Magentic.

About Magentic

Magentic provides AI digital workers, advanced multi-agent systems, that work alongside procurement and supply chain teams at global companies. Rather than adding another software dashboard, AI digital workers take action inside a company’s own systems. Founded by Robin Van Aeken (CEO) and Odhran O’Donoghue (CTO), Magentic launched in July 2025, is based in London and New York, and is backed by Sequoia Capital, Felicis, and The Westly Group.

Media contact 
media@magentic.com

SOURCE Magentic

The round marks a significant deepening of FIZE Medical’s strategic relationship with Asahi Kasei Medical, which launched FIZE kUO^® in Japan and serves as FIZE’s exclusive distribution partner in the country. Asahi Kasei Medical will now also distribute FIZE kUO^® in Europe, expanding FIZE Medical’s commercial reach into a major new market while strengthening the companies’ collaboration across critical care.

With this investment, Asahi Kasei Medical is expanding its involvement beyond distribution and into fluid management, signaling a deeper strategic commitment to FIZE Medical’s technology and its vision for the future of critical care. The partnership comes as FIZE Medical advances FIZE Optima, which is designed to harness continuous physiologic data to predict fluid-related risk and guide treatment decisions.

“Asahi Kasei Medical has been an important and trusted partner in bringing FIZE kUO to clinicians in Japan, and this investment represents a meaningful next step in our relationship,” said Dror Zerem, CEO of FIZE Medical. “We are moving beyond monitoring toward a future in which continuous patient data can help clinicians anticipate fluid-related risk and make more informed treatment decisions. Having Asahi Kasei Medical deepen its commitment to FIZE at this stage is a powerful validation of both our technology and vision.”

“As a world leader in development and production of devices and systems for blood treatment and purification, we already know this space well, and fluid management is a natural extension of our presence in critical care,” said Shuichiro Inadome, CEO of Asahi Kasei Medical. “We’re excited to deepen our partnership with FIZE Medical as it advances from precision monitoring toward predictive, AI-powered fluid management. We see significant potential in FIZE’s technology and look forward to expanding access to FIZE kUO in Europe.”

“Asahi Kasei Medical’s investment is a vote of confidence in FIZE Medical’s technology and trajectory,” said Kevin Slawin, M.D., Founder and Managing Partner of Rapha Capital Management. “We began investing in FIZE from its earliest stage because we believed in its potential to fundamentally change medicine through its groundbreaking kUO device. Today, we continue that commitment as FIZE establishes the kUO as the leading device in real-time kidney urine output data collection and takes the next step towards utilizing that data to deliver real-time fluid management solutions to clinicians when it’s needed most.”

Proceeds from the round will be used to accelerate development of the FIZE Optima platform for AI-driven prediction and treatment guidance, and to strengthen commercial activities in FIZE Medical’s leading markets.

About FIZE Medical

FIZE Medical is an innovative MedTech company dedicated to transforming fluid management for critically ill patients. Its proprietary FIZE kUO® system, commercially available in Japan, Europe and the U.S., provides real-time, digital monitoring to support precision fluid management, early intervention, and improved patient outcomes. FIZE Medical is committed to redefining fluid management through continuous innovation, AI-driven data insights, and clinical evidence.
https://fizemedical.com

About Asahi Kasei Medical Co., Ltd.

Asahi Kasei Medical Co., Ltd., headquartered in Tokyo, serves the global market with dialysis products and therapeutic apheresis devices, such as membrane type plasma separators, plasma component separators, and immunoadsorption columns. With a strong focus on intensive care, Asahi Kasei Medical is committed to advancing technologies that support healthcare professionals in improving outcomes and saving lives in the most critical clinical settings.

*Effective April 1, 2027, Asahi Kasei Medical Co., Ltd. will operate under the new company name “MILIFE CARE Corporation”.

https://www.asahi-kasei.co.jp/medical/

About Rapha Capital Management

Rapha Capital Management, LLC is an investment advisory firm focused on making strategic investments in early stage, non-public biotechnology companies, through special purpose, joint venture entities (SPVs), which it manages. Rapha Capital was founded by its President, Kevin Slawin, M.D., a successful and experienced urologist, oncologic and robotic surgeon focusing now on disruptive healthcare technologies. Previously, he was the founder of Bellicum Pharmaceuticals, Inc., the very first CAR-T cell company, which he took public in 2014 with a $55 million crossover Series C and a successful $161 million IPO in December 2014.

After leaving Bellicum, he founded Rapha Capital Management, LLC (https://raphacap.com), which offers alternative asset management services to Rapha’s fifteen SPVs, Rapha Capital Investment I to XV, LLC, as well as to its private equity fund, Rapha Capital PE Life Sciences Fund VI, which is the current vehicle for all investments managed by Rapha Capital Management.

For more information about Rapha Capital Management, email [email protected] or visit https://raphacap.com

Media Contact

Sharon Golubchik
RAYNZ
[email protected]

SOURCE FIZE Medical

The platform reconciles fragmented stock-market records to uncover discrepancies and preserve the evidence needed to investigate.

MONTREAL, Sept. 17, 2026 — BlueLedger AI Inc. (“BlueLedger”) today emerged from stealth at ALL IN 2026. Conflicting records can make it harder to verify ownership, establish payment entitlements or investigate suspected trading irregularities. BlueLedger helps issuers, counsel and market-integrity teams investigate those discrepancies, distinguishing supported findings from unresolved questions. The company is starting with paid issuer pilots, with retail access planned as the platform expands.

BlueLedger brings together public-company leadership, retail-investor research and financial intelligence. Co-Founder and Board Chair George Palikaras encountered the challenge inside a Nasdaq-listed company. CEO and Co-Founder Tiana Stoddart spent roughly three years manually tracing records with fellow investors. Co-Founder and Chief Science Officer Prof. Dhirendra Shukla brings expertise in entrepreneurial finance and financial intelligence, including Gray Wolf Analytics.

“Confidence in public markets depends on the ability to verify the records behind them. When those records conflict, issuers and investors need a reliable basis for investigation,” said Palikaras. “We are building BlueLedger to make reconciliation a core part of market oversight”.

“We compared filings, corporate-action records, identifiers and timelines, often moving between different systems and jurisdictions just to answer basic questions about the same security,” said Stoddart. “The information was there, but the complete story was not.”

“A discrepancy is a starting point for investigation, not a conclusion,” said Shukla. “The challenge is to establish whether records are genuinely comparable, account for differences in timing and context, and make uncertainty explicit.”

MaxWave Capital’s investment reflects its focus on governed intelligence for consequential decisions. Its portfolio also includes ARKEN, a separate company applying governed AI in industrial environments.

Peter J. Balafas, Managing Partner of MaxWave Capital, brings three decades of financial-industry experience to the firm’s investment thesis.

“An AI model alone is not a durable competitive advantage. The moat develops through domain expertise, reliable evidence and integration into the workflows clients depend on,” said Balafas. “With more than 50,000 listed companies worldwide, we see an opportunity to build trusted infrastructure for a global market.”

BlueLedger is headquartered in New Brunswick, where Prof. Shukla has ties to the innovation ecosystem. The company plans to build commercial capacity in the province for global markets and attract top talent in artificial intelligence and machine learning.

“I’m backing BlueLedger with my own capital and moving from Vancouver to New Brunswick to build it. The province’s Small Business Investor Tax Credit supports eligible investment, but the opportunity is bigger: to build a company here that serves global capital markets,” said Stoddart. “I want to help turn that opportunity into local talent development, innovation and lasting economic value.”

ALL IN 2026 takes place September 16–17 at the Palais des congrès de Montréal.

About BlueLedger AI Inc.

BlueLedger is building the evidence layer for trust in public markets. Its platform reconciles fragmented records across a security’s lifecycle to uncover discrepancies and preserve investigative evidence. Designed for issuers, counsel and market-integrity teams, BlueLedger distinguishes established findings from unresolved questions, with retail access planned. Headquartered in New Brunswick, Canada, BlueLedger is backed by MaxWave Capital. Visit blueledger.ai.

About MaxWave Capital Inc.

MaxWave is an operator-led independent sponsor focused on control-oriented private equity investments and special situations across North America and selectively in the UK and broader EMEA. The firm takes substantial ownership positions with negotiated governance rights in businesses facing operational complexity or transition. Drawing on experience in deep technology, capital markets and cross-border transactions, MaxWave works alongside management to set strategy, improve operations and execute growth plans. Learn more at maxwavecapital.com.

Media Contact

George Palikaras | 902 222 4423 | [email protected] |  blueledger.ai

SOURCE BlueLedger AI Inc.

New funding from leading artists and music industry executives—including Zach Bryan, Benny Blanco, Tainy, Ari Emanuel, Julie Greenwald, Sam Hendel, and others—supports the next phase of growth as Notes.fm builds a new financial layer for the music economy

Download Image Assets Here

NEW YORK, Sept. 17, 2026 — Notes.fm, the music royalty collection platform helping musicians and music companies identify and collect 100% of their royalties, announces it has raised $5 million from leading artists, managers, executives and strategic partners across the music industry. Notes is the latest venture from Stem co-founder Tim Luckow, on a mission to support independent artists with the best-in-class technology for distribution and publishing under one roof so they can have full control over their earnings and stop missing out on money that is rightfully theirs.

The round includes participation from a range of influential artists and music industry leaders from Benny Blanco, Zach Bryan and his managers Stefan Max and Danny Kang, Tainy, Blake Slatkin, and Mt. Joy frontman Matt Quinn, WME Group Executive Chairman Ari Emanuel, Chord Music founder Sam Hendel, longtime Atlantic Records chief and 26.2 founder Julie Greenwald, as well as many of the industry’s leading companies including Foundations, Mick Management, Twenty Ten Management, Triple 8, KMGMT, Good Boy, Mexican Summer, and Breakaway. The funding will support continued platform development and scaled marketing efforts as Notes expands its offering to artists globally.

Notes recently debuted a new feature “Releases” and unveiled its new partnership with Stripe, to streamline distribution, publishing admin and money management into one simplified release flow for musicians. This allows artists to use Notes.fm as the home for both distribution and royalty collection, making it easy for artists and their teams to take simultaneous ownership of their creative output and the income it generates. Notes is founded on the principle that every artist should receive all of their royalties. That’s why they take 0% participation in distribution and publishing royalties, charging a flat monthly subscription fee instead. It’s the same ethos behind their catalog royalty review technology, which helps rights owners identify missing royalties across their catalog and fix the issues so they can claim all of the royalties they’ve earned while they can.

This isn’t new for Notes. Since launch, they’ve rolled out capabilities that allow artists and rights holders to more seamlessly manage their earnings, including integrated financial accounts designed to give users more flexibility in how they collect, store, and transfer, and earn on income. These updates are part of a broader effort to build a more complete financial layer for the modern music ecosystem.

Prior to Releases, Notes also announced  Credits.fm, a free and open music credits database indexing more than 150 million song codes and credits to help the music industry organize, verify, and connect the data powering royalties and artist compensation in the age of AI.

“Music is evolving quickly, and the finance systems around it need to evolve at a faster rate,” said Tim Luckow, CEO and co-founder of Notes.fm. “Between all of the actions required to properly release, credit and collect on music, there are a lot of places where money falls through the cracks. We built Notes to bring all of that into one platform — so artists can release music and collect every royalty from day one, and recover what’s historically been missed.”

“Having spent our careers working with artists at every level, we’ve seen firsthand how much value gets lost to fragmented, unnecessarily complex systems,” adds co-founder Derek Davies. “The response to Notes from the music community has been incredibly meaningful, and we’re proud to announce a raise funded almost exclusively by artists, managers and music industry strategics who have a native understanding of these issues firsthand. This raise gives us the resources to keep building the infrastructure and applications that we believe the next generation of artists deserves.”

Notes has created an artist-friendly, automated process to simplify a notoriously complex and outdated system that has historically led to hundreds of millions of dollars in royalties going unclaimed by artists every year. Notes brings clarity to the complexity, requiring only a musician name and list of songs to start reviewing streaming services, collection societies, and registries like the MLC and SoundExchange. The platform not only identifies missing royalties, but it also helps an artist fix issues and directly claim the royalties that result from those corrections while ensuring future income flows correctly.

Following its public launch last year, Notes has already demonstrated strong early traction, identifying more than $10 million in previously unclaimed royalties across a broad range of artists and catalogs including James Blake, Zach Bryan, Mt. Joy, Girl In Red and more. The platform continues to grow across both emerging and established artists, reflecting a shared demand for greater clarity and access in how music earnings are tracked and distributed.

By bringing together royalty discovery, payments infrastructure, and music-centric financial management into a single experience, Notes.fm is helping to create a new system that better supports artists as their careers and audiences grow.

About Notes.fm
Notes.fm is a music royalty collection platform built to help independent musicians, artists and music companies collect all of their royalties in one easy-to-use place. Founded by Stem co-founder Tim Luckow, Notes brings distribution, publishing, and financial tools under one roof, giving musicians and companies the technology to release music, verify song credits, manage their catalogs, and collect every royalty they’re owed. Music Royalties, Simplified.

Learn more at www.notes.fm.

The Untold: Chelsey Northern ([email protected]), Chloé Snyder ([email protected]), Cory Councill ([email protected])

SOURCE Notes.fm

Condor’s announcement comes as looming patent cliffs across the pharmaceutical industry intensify pressure on companies to replenish their pipelines. While AI has accelerated drug discovery and increased the number of viable candidates, the financial infrastructure drug development runs on remains remarkably manual and labor intensive. When a budget, forecast, and actuals diverge, R&D teams can lose hours, if not days, reconciling data across ERPs, CTMS, EDC systems, and spreadsheets to better understand the financial impact behind the “why”. Lagging decisions have real consequences — like continuing to fund an underperforming site, discovering a change-order problem after negotiations are already underway, or waiting weeks to understand the financial implications of an enrollment change.

The clinical finance agent reasons across an organization’s full budget and forecast history in Condor to explain the “why” behind the numbers, identifying in seconds rather than hours what’s driving a variance between actuals and forecast or the cost to complete a given trial. It also runs full what-if scenario planning, modeling changes to site mix, enrollment timing, or financial investment, and then builds the resulting model directly in the platform. Powered by Condor’s proprietary knowledge graph and a deterministic math layer with AI reasoning on top, the agent is tuned to how R&D teams actually ask questions; not generic corporate forecasting logic. Additionally capabilities will be added to the agent soon.

Here’s how the agent works: you ask the questions that used to take your team weeks to prepare, and instantly get answers you can act on. For example, an R&D team’s clinical operations or finance leader can ask:

“Which sites in this trial are falling behind, and what does that mean for my budget, timeline, and enrollment?” Condor identifies the sites creating risk and connects their performance to the downstream impact on enrollment, timing, and cost.

“What will it cost to complete enrollment?” Condor calculates a cost-to-complete forecast based on the current state of the trial, without waiting weeks for a team to manually rebuild the model.

“Why did my change order increase?” Condor traces the increase back to the clinical and operational activity driving it and identifies where there may be an opportunity to reduce the cost.

To see the agent in action, book a demo at https://condorsoftware.com/contact.

The clinical finance agent is one of several agents in Condor AI Workflows — one of Condor’s three product pillars. Condor Connect automatically centralizes clinical, operational, and financial data with an understanding of a biopharma’s processes. Condor AI Workflows then automates various workflows — like budgeting, forecasts, month-end closes, accruals, and change order management. Condor AI Insights then surfaces patterns, flags risks, bridges context across functions, and delivers the “why” behind the numbers.

Supporting Quotes

“Drug development runs on two things: the science and the money that funds it. For decades, science was the bottleneck. AI and the patent cliff are closing that gap, and pipelines are about to fill with more candidates than this industry has ever had to fund. But the bottleneck didn’t disappear. It moved from the lab to the ledger. Every one of those candidates still has to be forecasted, funded, and managed, and the financial infrastructure doing that job still runs on spreadsheets. The pharmaceutical industry doesn’t have a data problem. It has a context problem. Companies have more data than they’ve ever had. But answering a basic question like ‘Why did this trial get more expensive?’ can still require people to hunt across multiple systems and rebuild the answer manually. We started Condor to eliminate that gap, and our new clinical finance agent takes us one huge step closer to realizing our mission of giving biopharma R&D teams the information they need to make clinical and financial decisions quickly and confidently.”

—Condor Founder and CEO Jen Kyle

“Quickly producing the ‘why’ behind the numbers is the biggest pain point that clinical operations and FP&A teams experience. Any system can tell you you’re five million over budget. That’s not useful on its own. You need to know in a clinical context what’s actually driving it, and you need to know fast. Our knowledge graph lets us answer that in a way generic AI can’t, because it intimately understands the context underpinning the clinical trial activities. And it doesn’t stop at the answer; it also builds the model. Our clinical finance agent is one of many Condor AI agents, each purpose-built to remove a specific piece of the manual work that slows R&D teams down.”

— Condor VP of Product Nim Fox

About Condor Software

Condor Software is the AI platform for biopharma R&D teams. It automatically centralizes clinical, operational, and financial data; automates various workflows — like budgeting, forecasts, month-end closes, accruals, and change order management; and then surfaces patterns, flags risks, bridges context across functions, and delivers the “why” behind the numbers. Founded by Jen Kyle, Condor is backed by Insight Partners, Felicis, 645 Ventures, Pamir Ventures, and SNR Ventures, and is trusted by leading biopharma companies worldwide — including Acadia Pharmaceuticals, BridgeBio Pharma, Madrigal Pharmaceuticals, and Stemline Therapeutics. Learn more at condorsoftware.com.

Media Contact:
Joseph Roualdes
[email protected]
415.823.2136

SOURCE Condor Software